临床试验/NCT06500598

NCT06500598Approved For Marketing不适用

Compassionate Use of Evinacumab

Regeneron Pharmaceuticals0 个研究点开始时间: 2024年7月15日最近更新: 2025年10月28日

研究概览

简要总结

Provide compassionate use of evinacumab

详细描述

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

研究设计

研究类型: Expanded Access

入排标准

入选标准

未提供

排除标准

未提供

研究者

发起方

Regeneron Pharmaceuticals

申办方类型

Industry

责任方

Sponsor

相似试验

Available

不适用

Compassionate Use or Expanded Access of Dupilumab

NCT04776694Regeneron Pharmaceuticals

已完成

3 期

Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial HypercholesterolemiaHomozygous Familial Hypercholesterolemia

NCT05611528Daniel Gaudet10

Approved For Marketing

不适用

Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver DiseaseCholestasisLiver Diseases

NCT03072667Catherine Cibulskis, MD

No Longer Available

不适用

Compassionate Use of Vidutolimod

NCT06063746Regeneron Pharmaceuticals

Available

不适用

Fremanezumab Managed Access Program for Pediatric PatientsMigraine

NCT03539393Teva Branded Pharmaceutical Products R&D LLC